BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

...By Paul Bonanos, Associate Editor With early efficacy signals emerging from a dose-finding study, Cyteir will...
...the only one in its class to reach the clinic.RA Capital led the round for Cyteir Therapeutics Inc....
...present data from the dose-escalation portion of a Phase I/II trial at a future medical meeting.Cyteir’s...
BioCentury | Oct 15, 2019
Finance

Cyteir synthetic lethality compound prompts Novo to lead $40M investment

...been watching for a while, according to Novo Ventures’ Karen Hong, who joined Cyteir’s board. “Cyteir...
...April, Cyteir had reopened its B round. “The timing was excellent,” Hong said, noting that Cyteir...
...functions while preventing it from participating in DNA damage repair (see “Cyteir: Stopping Shape-Shifters” ). Cyteir...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...describe synthetic lethal interactions involving the phosphatase DUSP1 ( No. 51 and No. 1341 ). Cyteir Therapeutics Inc....
...Therapeutics Inc., Watertown, Mass. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Cleveland Clinic, Cleveland, Ohio Cyteir Therapeutics Inc....
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...company BioAxone BioSciences Inc. (Cambridge, Mass.) hired Ronald Goldstein as CFO. He was CFO at Cyteir Therapeutics Inc....
BioCentury | Mar 16, 2018
Financial News

Cyteir raises $29M series B

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Cyteir Therapeutics Inc., Cambridge, Mass. Alicia Parker Cyteir Therapeutics Inc....
BioCentury | Mar 8, 2018
Financial News

Cyteir raises $29M series B

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...Bart Van Hooland joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Alicia Parker Cyteir Therapeutics Inc....
BioCentury | Dec 7, 2015
Company News

The Jackson Laboratory, Cyteir deal

...DNA repair enzymes. Cyteir said it will develop the compounds for cancer and autoimmune diseases. Cyteir...
...or royalties. Jackson did not respond to inquiries. The Jackson Laboratory , Bar Harbor, Maine Cyteir Therapeutics Inc....
BioCentury | Nov 16, 2015
Financial News

Cyteir completes venture financing

Cyteir Therapeutics Inc. , Cambridge, Mass. Business: Cancer, Autoimmune Date completed: 2015-11-05 Type: Venture financing Raised: $5.5 million Investors: Celgene Corp. ; private investors WIR Staff autoimmune cancer...
BioCentury | Jun 6, 2013
Distillery Therapeutics

Indication: Cancer

...preclinical development of new chemical entities derived from the RAD51 inhibitor used in the study. Cyteir Therapeutics Inc.'s...
...other AID-overexpressing malignancies. SciBX 6(22); doi:10.1038/scibx.2013.544 Published online June 6, 2013 Patent pending; licensed to Cyteir...
BioCentury | Jun 3, 2013
Emerging Company Profile

Cyteir: Stopping shape-shifters

...chance to work. "Genomic instability is one of the most defining features of tumors," said Cyteir...
...NSCLC). In 2011, iniparib failed in a Phase III trial in metastatic triple-negative breast cancer. Cyteir...
...the proof-of-concept findings in the Journal of Experimental Medicine in April. Last year, Mills launched Cyteir...
Items per page:
1 - 10 of 10
BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

...By Paul Bonanos, Associate Editor With early efficacy signals emerging from a dose-finding study, Cyteir will...
...the only one in its class to reach the clinic.RA Capital led the round for Cyteir Therapeutics Inc....
...present data from the dose-escalation portion of a Phase I/II trial at a future medical meeting.Cyteir’s...
BioCentury | Oct 15, 2019
Finance

Cyteir synthetic lethality compound prompts Novo to lead $40M investment

...been watching for a while, according to Novo Ventures’ Karen Hong, who joined Cyteir’s board. “Cyteir...
...April, Cyteir had reopened its B round. “The timing was excellent,” Hong said, noting that Cyteir...
...functions while preventing it from participating in DNA damage repair (see “Cyteir: Stopping Shape-Shifters” ). Cyteir...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...describe synthetic lethal interactions involving the phosphatase DUSP1 ( No. 51 and No. 1341 ). Cyteir Therapeutics Inc....
...Therapeutics Inc., Watertown, Mass. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Cleveland Clinic, Cleveland, Ohio Cyteir Therapeutics Inc....
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...company BioAxone BioSciences Inc. (Cambridge, Mass.) hired Ronald Goldstein as CFO. He was CFO at Cyteir Therapeutics Inc....
BioCentury | Mar 16, 2018
Financial News

Cyteir raises $29M series B

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Cyteir Therapeutics Inc., Cambridge, Mass. Alicia Parker Cyteir Therapeutics Inc....
BioCentury | Mar 8, 2018
Financial News

Cyteir raises $29M series B

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...Bart Van Hooland joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Alicia Parker Cyteir Therapeutics Inc....
BioCentury | Dec 7, 2015
Company News

The Jackson Laboratory, Cyteir deal

...DNA repair enzymes. Cyteir said it will develop the compounds for cancer and autoimmune diseases. Cyteir...
...or royalties. Jackson did not respond to inquiries. The Jackson Laboratory , Bar Harbor, Maine Cyteir Therapeutics Inc....
BioCentury | Nov 16, 2015
Financial News

Cyteir completes venture financing

Cyteir Therapeutics Inc. , Cambridge, Mass. Business: Cancer, Autoimmune Date completed: 2015-11-05 Type: Venture financing Raised: $5.5 million Investors: Celgene Corp. ; private investors WIR Staff autoimmune cancer...
BioCentury | Jun 6, 2013
Distillery Therapeutics

Indication: Cancer

...preclinical development of new chemical entities derived from the RAD51 inhibitor used in the study. Cyteir Therapeutics Inc.'s...
...other AID-overexpressing malignancies. SciBX 6(22); doi:10.1038/scibx.2013.544 Published online June 6, 2013 Patent pending; licensed to Cyteir...
BioCentury | Jun 3, 2013
Emerging Company Profile

Cyteir: Stopping shape-shifters

...chance to work. "Genomic instability is one of the most defining features of tumors," said Cyteir...
...NSCLC). In 2011, iniparib failed in a Phase III trial in metastatic triple-negative breast cancer. Cyteir...
...the proof-of-concept findings in the Journal of Experimental Medicine in April. Last year, Mills launched Cyteir...
Items per page:
1 - 10 of 10